The Agency shall, in collaboration with the Member States, develop standard web-based structured forms for the reporting of suspected adverse reactions by healthcare professionals and patients in accordance with the provisions referred to in Article 107a of Directive 2001/83/EC.
Art. 25 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…
Directive (EU) 2001/83106107a107eLaw
… включително структурираните формуляри в интернет, посочени в член 25 от Регламент (ЕО) № 726/2004.
… включително структурираните формуляри в интернет, посочени в член 25 от Регламент (ЕО) № 726/2004. 1. Веднага щом титулярят на …
Gesetz über den Verkehr mit Arzneimitteln80Law
… 1 und Artikel 25 der Verordnung (EG) Nr. 726/2004. Dabei können auch Regelungen für Arzneimittel getroffen werden, die unter den Artikel 83 der Verordnung (EG) Nr. 726/2004 entsprechenden Voraussetzungen Arzneimittel betreffen, die nicht …
Règlement grand-ducal du 15 décembre 1992 relatif à la mise sur le marché des médicaments.45-1Law
… par les professionnels de la santé et les patients, dont les formulaires structurés mis en ligne visés à l’article 25 du règlement (CE) n° 726/2004; les informations importantes relatives aux questions de pharmacovigilance liées …
Opinion of Advocate General Saugmandsgaard Øe delivered on 25 July 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and OthersDecision
By its request for a preliminary ruling, the Consiglio di Stato (Council of State, Italy) asks the Court of Justice to interpret Articles 3(1), 5(1) and 6(1) of Directive 2001/83/EC, [Directive of the European Parliament and of the Council …
25 Jul 2018 · 62017CC0029
The Human Medicines Regulations 2012203Law
… care professionals, coroners or procurators fiscal (including by way of the web-based structured forms referred to in Article 25 of Regulation (EC) No 726/2004).
Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decisioninterprets
This request for a preliminary ruling concerns the interpretation of Articles 3(1), 5 and 6 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for …
21 Nov 2018 · 62017CJ0029
Règlement grand-ducal du 10 septembre 2012 modifiant le règlement grand-ducal modifié du…1Law
… par les professionnels de la santé et les patients, dont les formulaires structurés mis en ligne visés à l’article 25 du règlement (CE) n° 726/2004; les informations importantes relatives aux questions de pharmacovigilance liées …
… bestimmt sind, an die zuständigen Behörden durch Angehörige der Gesundheitsberufe und Patienten sowie die in Artikel 25 der Verordnung (EG) Nr. 726/2004 genannten Internetformulare für die Meldung von Verdachtsfällen von …
Changed on 2 Jul 2012
Each Member State The Agency shall ensure that all suspected serious adverse reactions occurring within their territory to a medicinal product for human use authorised in accordance, in collaboration with this Regulation which are brought to their attention are recorded and reported promptly to the Agency and the marketing authorisation holder, and no later than 15 days following receipt of the information.
The Agency shall forward the information to the national pharmacovigilance systems set up in accordance with the Member States, develop standard web-based structured forms for the reporting of suspected adverse reactions by healthcare professionals and patients in accordance with the provisions referred to in Article 102107a of Directive 2001/83/EC.
- 2 Jul 2012 – todayin force
- 31 Mar 2004 – 2 Jul 2012earlier wording